NCT01698801 · REGISTRY CONDITION SEARCH

A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2018-11-08

To determine the efficacy of lenalidomide in combination with low-dose dexamethasone in Japanese subjects with previously untreated multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Time to Response

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Progression Free Survival (PFS)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Number of Participants With Adverse Events

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Age ≥ 20 years at the time of signing the informed consent document * Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted * Able to adhere to the study visit schedule and other protocol requirements * Previously untreated, symptomatic multiple myeloma * Have measurable disease by protein electrophoresis analyses * At least 65 years of age or older or, if younger than 65 years of age, not candidates for hematopoietic stem cell transplantation * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Must agree to comply to Lenalidomide Pregnancy Prevention Risk Management Plan Exclusion Criteria: * Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study * Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study * Any condition that confounds the ability to interpret data from the study * Previous treatment with anti-myeloma therapy * Pregnant or lactating females * Any of the following laboratory abnormalities: * Absolute neutrophil count (ANC) \< 1,000/microL (1.0 × 10\^9/L ) * Untransfused platelet count (a platelet count drawn at least 7 days after the administration of the last platelet transfusion) \< 50,000 cells/microL (50 × 10\^9/L) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3.0 × upper limit of normal * Renal failure requiring hemodialysis or peritoneal dialysis * Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years * Subjects who are unable or unwilling to undergo antithrombotic therapy. * Peripheral neuropathy of ≥ grade 2 severity. * Uncontrolled systemic fungal, bacterial, or viral infection * Known human immunodeficiency virus (HIV) positivity (subjects who are receiving antiretroviral therapy for HIV disease) * Hepatitis Bs (HBs) antigen-positive, or hepatitis C virus (HCV) antibody-positive. In case HBc antibody and/or HBs antibody is positive even if HBs antigen-negative, a Hepatitis B virus (HBV) DNA test should be performed and if positive the subject will be excluded. * Primary AL (immunoglobulin light chain) amyloidosis and myeloma complicated by amyloidosis. * Ineligible for dexamethasone or dexamethasone is contraindicated.
healthy Volunteers: false
minimum Age: 20 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Lenalidomide plus low-dose dexamethasone
intervention Names
Drug: Lenalidomide
Drug: dexamethasone
label
Lenalidomide plus dexamethasone
type
EXPERIMENTAL

interventions

arm Group Labels
Lenalidomide plus dexamethasone
description
25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
name
Lenalidomide
other Names
Revlimid
type
DRUG
arm Group Labels
Lenalidomide plus dexamethasone
description
40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
name
dexamethasone
other Names
LenaDex
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 26
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Number of Complete Responses (CR) plus Very Good Partial Response (VGPR) plus Partial Response (PR) based on the International Myeloma Working Group criteria (IMWG). Any participant who achieved a CR, VGPR, or PR while on study treatment was defined as a responder. CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.
measure
Overall Response Rate
time Frame
From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.

secondary Outcomes

description
Time to response was calculated for the responders as the time from the first dose date to the initial documented response (CR, VGPR or PR). CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.
measure
Time to Response
time Frame
From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow-up time was 61.6 weeks.
description
Duration of response was calculated for the responders as the time from the initial documented response (CR or VGPR or PR) to the first documented progression or death due to any cause, whichever occurred first. Duration of response for participants last known to be alive with no progression after a CR, VGPR, or PR were censored at the date of last adequate response assessment.
measure
Duration of Response
time Frame
From the first dose of study drug treatment until the data cut-off date of 15 July2014. Median follow up time was 61.6 weeks.
description
PFS was calculated as the time from the first dose date to the first documented progression based on IWG criteria or death due to any cause, whichever occurred first. If progression or death was not documented at the time of data cutoff date, these observations were censored at the last adequate assessment date showing evidence of no progression or death.
measure
Progression Free Survival (PFS)
time Frame
From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow-up for PFS assessments was 61.6 weeks.
description
The time from the start of study treatment to death due to any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
measure
Overall Survival (OS)
time Frame
From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow up is 14.2 months
description
An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required);-Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.
measure
Number of Participants With Adverse Events
time Frame
From first dose of study drug treatment through to 28 days after the last dose, until the data cut-off date of 15 July 2014; median treatment duration was 60 weeks

Full study description

brief Summary: To determine the efficacy of lenalidomide in combination with low-dose dexamethasone in Japanese subjects with previously untreated multiple myeloma.

Source references

references

citation
Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Ogawa Y, Shimizu T, Otsuka M, Matsumoto M, Iida S, Terui Y, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Chou T. Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. Cancer Sci. 2016 May;107(5):653-8. doi: 10.1111/cas.12916. Epub 2016 Mar 30.
pmid
26914369
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-1fb93bfa5ff389dd49d7
requested nct id
NCT01698801
primary nct id
NCT01698801
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
274d43e994cb3ba1a8b375ce9120f55a3c088f61ca8648e95415d5dc0e3c97df
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-1fb93bfa5ff389dd49d7
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01698801
occurrences
context exact
NCT01698801
end
11
exact text
NCT01698801
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/723/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
71ae3044cc2cc60805e30597514955aef27fbbea8f745ef648545d6cb22b35f1
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice